Rapid AI generation of optimised compound designs, guided by user interaction
Pairing AI with human expertise We present a novel AI compound optimisation system, designed to include human oversight as a…
Combining deep learning with multi-parameter optimisation to predict compounds with selective activity against a broadleaf weed species
Introduction The emergence of resistance and increased stringency of regulatory requirements have created a need for new agrochemicals. The long…
Explaining the ‘black box’: deep learning in drug discovery
Recent years have seen a remarkable rise in the number and scope of artificial intelligence and machine learning (especially deep…
Avoid the hype – how to successfully implement AI in drug discovery
AI has the potential to transform discovery. However, to ensure real impact, there are several practicalities that organisations must consider…
Real world case studies: Predicting pharmacokinetics from limited ADME data with deep learning
Now, watch Matt Segall, PhD, CEO at Optibrium, as he introduces a real world case study where we applied deep learning to guide a project, in which potential compounds were displaying good activity profiles but the team wanted to improve their PK profile to achieve better efficacy.
The power of AI applied to agrochemical bioactivity
In the face of growing agrochemical resistance and increasingly stringent regulatory requirements, how can artificial intelligence (AI) be harnessed to help lower the costs, failure rates and timelines associated with current agrochemical development cycles?
Transformative insights from your data in CDD vault with Cerella AI
In this webinar, learn about Cerella’s unique AI methods, see examples of its successful application throughout the drug discovery process and watch a demonstration of how CDD Vault and Cerella connect to seamlessly integrate with your workflows.
Perfecting the use of imperfect QSAR models
In this webinar, we examine the effective use of QSAR modelling in drug discovery and discuss a variety of pain points for medicinal chemists in knowing when a model can be trusted and how to avoid common pitfalls.
AI in early drug discovery: from promise to practice
In this webinar, Jeff Blaney (Senior Director of Discovery Chemistry, Genentech), Darren Green (Head of Cheminformatics & Data Science, GlaxoSmithKline), Julian Levell (Head of Discovery, New Equilibrium Biosciences), Matthew Segall (CEO, Optibrium) discuss the state of AI in early drug discovery from hit to preclinical candidate and share their experiences with and expectations of AI, including predictive modelling, synthesis prediction, and generative chemistry. Hear about the successes of AI drug discovery and an outlook on what AI needs to achieve to really transform the industry.
AI Solutions from hit to candidate
In this webinar, we explore the highlights of collaborative project results that demonstrate how every phase of the drug discovery process can be radically improved by applying proven AI technology. Providing scientists with insights on which to base decisions can identify valuable new opportunities and reduce the time and cost of AI drug discovery cycles.
We review case studies from collaborations with Constellation Pharmaceuticals, AstraZeneca, Genentech, the University of Dundee and Takeda Pharmaceuticals to validate the impact of applying AI to experimental data and illustrate dramatic improvements to their project outcomes.
Join Samar Mahmoud and Matt Segall for this fascinating deep dive into the revolution that AI is bringing to the challenges of sparse and noisy drug discovery data.
Optimising kinase profiling programmes with deep learning
In this webinar, we discuss Alchemite™, a novel deep learning approach, and its application to optimising kinase profiling programmes. The…
A global deep learning model for global health drug discovery
In this webinar, we described the generation and validation of a ‘global’ model using deep learning imputation on a data set of 300,000 compounds and 500 experimental endpoints, targeting global health indications.
We demonstrated how this global model can be applied to individual optimisation projects, offering improved compounds design performance over ‘local’ project-specific models by learning across a broad chemical diversity.
Cerella™: Reduce the time and cost of your discovery cycles with deep learning
In this webinar, we demonstrate how Cerella™ (AI drug discovery software) highlights new opportunities and guides more efficient compound optimisation.
Informatics for effective drug discovery
Learn how advances in informatics technology are inspiring a new generation of innovative products that streamline and enhance the efficiency and productivity of drug discovery software.
Deploying Cerella for active learning using deep learning imputation
In this webinar we demonstrated how this new platform provides interactive access to deep learning imputation to extract more value…
Large scale imputation of drug discovery data using deep learning
We presented a case study in which Alchemite was applied to a data set comprising approximately 700,000 compounds and 1,000…
AI-guided design of antimalarials with In vitro validation
In this webinar you can hear how a combination of generative chemistry and deep learning has impacted the design of…
Practical applications of deep learning to imputation of drug discovery data
In this webinar, we explore how the limitations of pharmaceutical data can impact conventional predictive model building. Our speakers, Julian Levell (Constellation pharmaceuticals), Ben Irwin and matt Segall (Optibrium) demonstrate how the deep learning imputation algorithm underlying our Cerella platform, overcomes these challenges.
